Molecure S.A.

WSE:MOC Voorraadrapport

Marktkapitalisatie: zł173.4m

Molecure Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Marcin Szumowski

Algemeen directeur

zł473.2k

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEOno data
Eigendom CEO0.7%
Management gemiddelde ambtstermijn3.8yrs
Gemiddelde ambtstermijn bestuur2.8yrs

Recente managementupdates

Recent updates

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Aug 20
Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Apr 20
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Dec 01
We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Jul 07
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Mar 10
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Aug 16
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Nov 04
OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Feb 24
Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Jan 02
Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

CEO

Marcin Szumowski

no data

Tenure

zł473,205

Compensatie

Dr. Marcin Jan Szumowski, Ph D., is employed at Life Science Innovations Fund. He has been Chief Executive Officer and President of the Management Board at Molecure S.A. (formerly known as OncoArendi Thera...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Marcin Szumowski
Co-Founderno datazł473.21k0.70%
PLN 1.2m
Slawomir Broniarek
CFO & Member of the Management Boardno datazł421.09k0.20%
PLN 355.4k
Zbigniew Zaslona
Chief Scientific Officer & Member of Management Board2.8yrszł473.21k0.11%
PLN 194.6k
Agnieszka Rajczuk-Szczepanska
Member of Management Board & HR Director4.8yrszł348.41k0.034%
PLN 59.7k
Adam Golebiowski
Co-Founder & VP of Research Chemistry12.8yrszł500.00k3.01%
PLN 5.2m
Jacek Olczak
Co-Founder & Head of Medicinal Chemistryno datageen gegevensgeen gegevens
Piotr Iwanowski
Chief Medical Officer & Member of Management Boardless than a yeargeen gegevensgeen gegevens
Magdalena Tyszkiewicz
Head of CMC4.8yrsgeen gegevensgeen gegevens
Marta Borkowska
Director of the Management Board Office2.8yrsgeen gegevensgeen gegevens

3.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van MOC wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Luke O'Neill
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Bart Lambrecht
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Tomasz Piec
Vice Chairman of the Supervisory Board4.8yrszł133.62kgeen gegevens
Douglas Hay
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Paul Van Der Horst
Independent Chairman of the Supervisory Board2.8yrszł132.99k0.059%
PLN 103.0k
Nancy Van Osselaer
Independent Member of the Supervisory Board2.8yrszł124.22kgeen gegevens
Agnieszka Motyl
Member of the Supervisory Board1.3yrszł44.45kgeen gegevens
Pawel Trawkowski
Independent Member of the Supervisory Board2.4yrszł124.22kgeen gegevens

2.8yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van MOC wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.8 jaar), wat duidt op een nieuw bestuur.